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Key Points
• f5 mutant fish embryos
tolerate symptoms le-
thal in mammals but
succumb to bleeding in
adulthood.
• Analysis of patient F5
variants demonstrate
that all have some re-
sidual ability to restore
hemostasis in response
to endothelial injury.
In humans, coagulation factor V (FV) deficiency is a rare, clinically heterogeneous bleeding
disorder, suggesting that genetic modifiers may contribute to disease expressivity. Zebrafish
possess many distinct advantages including high fecundity, optical clarity, external
development, and homology with the mammalian hemostatic system, features that make it
ideal for genetic studies. Our aim was to study the role of FV in zebrafish through targeted
mutagenesis and apply the model to the study of human F5 variants. CRISPR-mediated
genome editing of the zebrafish f5 locus was performed, generating mutants homozygous
for a 49 base pair deletion in exon 4. Thrombus formation secondary to vascular
endothelial injury was absent in f52/2 mutant embryos and larvae. Despite this severe
hemostatic defect, homozygous mutants survived before succumbing to severe hemorrhage
in adulthood. Human F5 variants of uncertain significance from patients with FV deficiency
were evaluated, and the causative mutations identified and stratified by their ability to
restore thrombus formation in larvae. Analysis of these novel mutations demonstrates
variable residual FV function, with minimal activity being required to restore hemostasis
in response to laser-induced endothelial injury. This in vivo evaluation may be beneficial
for patients whose factor activity levels lack correlation with bleeding symptomatology,
although limitations exist. Furthermore, homozygous mutant embryos tolerate what is a
severe and lethal defect in mammals, suggesting the possibility of species-specific factors
enabling survival, and allowing further study not possible in the mouse. Identification of
these factors or other genetic modifiers could lead to novel therapeutic modalities.
Introduction
Coagulation factor V (FV, gene F5) is an essential component of hemostasis. In plasma, it circulates as a
large 330 kDa glycoprotein that shares homology and a similar domain organization with factor VIII.1,2
The inactive pro-cofactor form of FV is synthesized in the liver as a 2224 amino acid polypeptide,
secreted as a 2196 amino acid single chain protein, and the large B domain is removed during activation.
In its activated form, FVa serves as the cofactor protein for the activated serine protease factor Xa
(FXa, gene F10) in the prothrombinase complex, which rapidly converts prothrombin to thrombin.
The gene for FV is located on the long arm of chromosome 1, band 23, consists of 25 exons, and
is ;80 kb in length.3
Congenital deficiency of FV in humans is a rare autosomal recessive bleeding disorder that affects 1 in
1 000 000 individuals, the vast majority resulting from null mutations.4-7 FV deficiency is divided into
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type I (quantitative) and type II (qualitative) defects, with the majority
of mutations falling in the former group.8 Treatment options are
limited, because only recently has a purified FV concentration been
developed.9 Multifactor concentrates contain inadequate concen-
trations of FV to be effective. For major bleeding, fresh frozen plasma
or platelet transfusions are typically used.4 For minor bleeding,
antifibrinolytics are often sufficient.6
Insight into the crucial role of FV has been facilitated using gene
targeting in mice. F5 knockouts exhibit complete lethality, with death
in either the embryonic or perinatal periods,10 although transgenic
expression of very small amounts (,0.1%) of F5 rescues this
phenotype.11 In humans, levels of FV antigen do not correlate well
with bleeding symptomatology. In patients with severe FV defi-
ciency (levels ,1%), mucosal bleeding is seen most commonly.
Fewer patients present with menorrhagia, hematomas, and
hemarthroses.12 The relatively mild bleeding seen in many patients
with severe deficiency may be explained by findings that,1% FV is
adequate to ensure minimal thrombin generation as demonstrated
in in vivo,13 in vitro,14 and in silico15 studies. However, this does not
explain the striking variability in phenotype between patients with
equivalent FV levels. This variability may be explained in some
patients by residual platelet FV, as well as low levels of tissue factor
pathway inhibitor.16,17
Zebrafish (Danio rerio) have been used extensively to study
hemostasis and have demonstrated significant homology with the
mammalian coagulation system. They possess distinct advantages,
including high fecundity, optical clarity, and external development.
New developments in genome editing technology have facilitated
quick and robust systems for targeted genetic modification.18-20
We and others have demonstrated the benefits of this system for
modeling hemostasis and thrombosis.21-33 Knockout models have
demonstrated longer than expected survival in comparison with
their mammalian counterparts,24,34,35 enabling additional charac-
terization of the phenotypes. We previously demonstrated a severe
hemostatic defect in FX-deficient zebrafish early in development
with lack of venous occlusion in response to endothelial injury
at 3 days postfertilization (dpf).35 Homozygous mutants tolerate
this defect with no overt hemorrhage until 3 to 4 weeks of age and
survival for several months. Anticoagulant deficiency has also been
shown to exhibit milder phenotypes in the zebrafish in comparison
with murine models. A zebrafish model of antithrombin (At3)
deficiency exhibited a phenotype similar to disseminated intravas-
cular coagulation.24 Despite this, homozygous mutants lived to
adulthood, in contrast to the prenatal mortality observed in
mice.24,36 Here we report targeted ablation of zebrafish f5 using
the CRISPR/Cas9 genome editing platform. Homozygous mutant
embryos and larvae demonstrate a severe defect in hemostasis.
They tolerate this into adulthood, but eventually succumb to lethal
bleeding by 6 months of age.
Methods
Zebrafish strains and maintenance
Zebrafish were raised in accordance with animal care guidelines
as approved by the University of Michigan Animal Care and
Use Committee. Embryos are defined as 0 to 2 dpf, larvae
3 to 29 dpf, juvenile 30 to 89 dpf, and adult $90 dpf.37
f5 mutant zebrafish were generated on an AB 3 TL hybrid
background.
Targeted mutagenesis of the f5 locus using
CRISPR/Cas9 genome editing
The f5 locus was identified in the zebrafish genomic sequence
assembly38 and CRISPR/Cas9-mediated genome editing was used
to induce mutations in exon 4. Target sites of 17 to 20 nucleotides
were identified using the Web-based ZiFiT Targeter program
(http://zifit.partners.org) as described elsewhere.39 Templates for
synthetic single-guide RNAs (sgRNAs) were constructed using
polymerase chain reaction (PCR) to fuse overlapping oligonucleo-
tides (Integrated DNA Technologies, Coralville, IA), which contained
the complementary 20 nucleotides of the target site, the T7 promoter,
and linearized vector pDR27440 as a template (Table 1). The resulting
double-stranded DNA fragment (120 base pairs) was then column
purified and transcribed using the T7 Quick High Yield RNA
Synthesis kit (New England BioLabs, Ipswich, MA) and purified
using RNA Clean and Concentrator kit (Zymo Research, Irvine,
CA). Cas9 messenger RNA (mRNA) was transcribed as previously
described.20 sgRNAs and Cas9 mRNA were injected concurrently
into the cytoplasm of 1-cell stage embryos at concentrations of
12.5 and 300 ng/mL, respectively. The resulting F0 population was
raised to adulthood and crossed with wild-type zebrafish to verify
germline transmission to the F1 generation.
Genotyping of f5 mutant offspring
Staged zebrafish larvae or adults were anesthetized in tricaine
(0.16 mg/mL, Western Chemical Inc., Ferndale, WA) or humanely
euthanized in high-dose tricaine (1.6 mg/mL). Fish were tail fin-
clipped as described previously.24,41 Genomic DNAwas isolated by
incubating tissue in lysis buffer (10 mM Tris-Cl, pH 8.0; 2 mM EDTA,
2% Triton X-100, and 100 mg/mL proteinase K) at 55°C overnight,
followed by proteinase K inactivation at 95°C for 5 minutes.24
Insertion and deletion mutations were detected by PCR and
resolved by agarose gel electrophoresis or using a Qiaxcel (Qiagen,
Hilden, Germany). Primers were designed using Primer342 and
oligonucleotides ordered from Integrated DNA Technologies
(Table 1).
Laser-induced endothelial injury in zebrafish larvae
Laser-mediated endothelial injury was performed on the posterior
cardinal vein (PCV) of zebrafish larvae at 3 dpf as described.25
Larvae were anesthetized in tricaine, embedded in 0.8% low-melt
agarose on glass cover slips, and the endothelium of the PCV at the
fifth somite distal to the anal pore was ablated using 100 pulses at
power level 18 (MicroPoint Pulsed Laser System, Andor Technol-
ogy, Belfast, Northern Ireland). Arterial injury was also performed on
the dorsal aorta at the fifth somite distal to the anal pore at 9 dpf and
endothelial injury to the primordial midbrain channel (PMBC) just
lateral to the otic capsule at 6 to 7 dpf. The time to occlusion was
recorded for up to 2 minutes by a blinded observer. Larvae were
subsequently recovered from agarose and genotyped.
Construction of f5 in vivo expression vectors
pDestTol2pA2_ubi:p2A-EGFP35 contains a BbsI restriction site
flanked multiple cloning site and a self-cleaving p2A peptide 59 to
the egfp sequence. The vector was linearized using BbsI and
purified. The D rerio f5 complementary DNA (cDNA) was amplified
from plasmid MDR1734-202728340 (Dharmacon, Lafayette, CO)
using primers with f5 and vector homology (Table 1). The resulting
6.3-kb product was purified and inserted into BbsI linearized
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pDestTol2pA2_ubi:p2A-EGFP using In-Fusion Cloning (Clontech,
Mountainview, CA) and transformed into high efficiency 10-b
competent Escherichia coli (New England BioLabs) to generate
pDestTol2pA2_ubi:f5-p2A-EGFP. Positive colonies were grown in LB
media supplemented with 50 mg/mL ampicillin and sequence verified.
Mutations were introduced using the QuickChange XL II site-directed
mutagenesis kit (Agilent) and mutation-specific primers (Table 1).
Amino acid numbering reflects the human amino acid position.
One-cell injection of f5 expression vectors
Circular f5 expression plasmids (10 ng/mL) and transposase mRNA
(50 ng/mL)43 were coinjected into 1-cell stage embryos from
f5D491/2 incrosses. Fluorescent embryos were selected at 3 dpf
for laser-mediated endothelial injury.
Whole mount in situ hybridization
Inhibition of pigmentation in embryos and larvae was accomplished
using 0.2 mM phenylthiourea (Sigma-Aldrich, St. Louis, MO) at
24 hours postfertilization. Staged larvae were fixed in 4% parafor-
maldehyde in phosphate-buffered saline with 0.01% Tween-20 at
4°C overnight. They were then dehydrated stepwise into 100%
ethanol. Partial f5 cDNA fragments were amplified to synthesize
sense and antisense digoxin-labeled RNA riboprobes (DIG RNA
labeling kit, Roche, Basel, Switzerland) (Table 1). Amplification of
cDNA templates, synthesis of riboprobes, and whole mount in situ
hybridization were performed as previously described.24,44,45
RNA isolation, cDNA generation, and reverse
transcription PCR
Larvae at 4 dpf were euthanized in high-dose tricaine, tissue
removed for genotyping, and then placed in RLT plus buffer
(Qiagen); 21 of each genotype were divided into 3 pools of 7 for
RNA extraction. Total RNA was isolated using RNEasy Plus Mini Kit
(Qiagen) and reverse transcribed with Superscript III Synthesis
(Invitrogen). cDNAs were amplified using PrimeTime qPCR Gene
Expression Master Mix (Integrated DNA Technologies).
Chemical treatment of embryos
Embryos were incubated in 100 mM e-aminocaproic acid (Sigma-
Aldrich) dissolved in system water starting at 24 hours postfertilization
and continuing until 3 dpf. At 3 dpf, they were evaluated by laser-
mediated endothelial injury.
Results
Targeted disruption of f5 using genome editing
nucleases results in spontaneous hemorrhage and
adult lethality
We used CRISPR-Cas9 genome editing to target f5. Several
sgRNAs were constructed to target exon 4 of the zebrafish f5
genomic locus. The most robust sgRNA resulted in somatic
mutations at a frequency of 66.4%. The resulting embryos were
Table 1. Primers used in experimental procedures
Primer Sequence Description
1 AAAAATAATACGACTCACTATAGGTGGGTCTGCAGCTGTA 59 gRNA amplification primer (polyA, T7, target sequence, target underlined)
2 GGTGGGTCTGCAGCTGTAGTTTTAGAGCTAGAAAT Target sequence, 59 pDR274 primer (target underlined)
3 AAAAGCACCGACTCGGTGCC 39 pDR274 primer
4 TTGACAACACGTCACTCCTTG 59 genotyping primer
5 TTCTTGCAGATCAGCATTGG 39 genotyping primer
6 CAGGCTGGACCAAAACAGACAGAACGTTTCTACC cDNA amplification primer (vector homology underlined)
7 GCTCCGCTTCCATAGCATTCGAAATCACAACCC cDNA amplification primer (vector homology underlined)
8 GGAACATGGCAGATCATCCT 59 primer for in situ probe
9 GGTAATACGACTCACTATAGcccagcaggtgccagctgac 39 primer for in situ probe with T7 promoter
10 TCCCCTAAAAATGCATGTCTGT 59 intron based genotyping primer
11 CAAGGCATCTCAGCATGAACA 39 intron based genotyping primer
12 GCAGATCATCCTTGCcGCCTCCACCCtCATGGCATTGC p.S83R (D rerio 102) 59 primer
13 GCAATGCCATGaGGGTGGAGGCgGCAAGGATGATCTGC p.S83R (D rerio 102) 39 primer
14 CGGGAAGCAGTCAGAGGacTCTTTATACTTTGACAACACG p.G97D (D rerio 116) 59 primer
15 CGTGTTGTCAAAGTATAAAGAgtCCTCTGACTGCTTCCCG p.G97D (D rerio 116) 39 primer
16 GCCGAACTTGGACCTgCTACTCcGCAGTGAATCCTGAGAG p.Y1702C (D rerio 1596) 59 primer
17 CTCTCAGGATTCACTGCgGAGTAGcAGGTCCAAGTTCGGC p.Y1702C (D rerio 1596) 39 primer
18 GGCATCCTTGGTATGCatGCCTAAATAAACAAGGAACCGC p.R2074C (D rerio 1965) 59 primer
19 GCGGTTCCTTGTTTATTTAGGCatGCATACCAAGGATGCC p.R2074C (D rerio 1965) 39 primer
20 GCAGAAATCCGTCACCATGtGtATTGAGCTcCTGGGTTGTG p.R2187C (D rerio 2092) 59 primer
21 CACAACCCAGgAGCTCAATaCaCATGGTGACGGATTTCTGC p.R2187C (D rerio 2092) 39 primer
22 CGGAAGATAAGCAGAGGAAGAG) qPCR forward primer
23 AGAGCTTGGAATTCTTGGCCCAGT qPCR probe
24 ACTATAGGGACGTGATGCTTTG qPCR reverse primer
qPCR, quantitative PCR.
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raised to adulthood and F0 founders were mated to wild-type fish to
verify germline transmission. We identified many potential founders
and verified 1 for further analysis, a 49-bp deletion (f5D49 hereafter
referred to as f52) within the predicted A1 domain (Figure 1A-B).
The mutation was confirmed both at the genomic and cDNA levels
(Figure 1C-D). Heterozygotes from each line were incrossed, and
genotyping before 1 month of age revealed a normal Mende-
lian distribution. Beginning at 28 dpf, we observed a statistically
significant loss of homozygotes, and by 7 months postfertilization
(mpf),;90% died (P, .0001) (Figure 2A-B). Interestingly, we saw
a significant loss of heterozygotes starting around 18 months of
age (P 5 .04). Spontaneous hemorrhage was observed grossly in
homozygous mutants beginning around 28 dpf, coincident with the
beginning of observed lethality (Figure 2C-D).
Zebrafish embryos and larvae show no signs of
overt hemorrhage
Loss of F5 in mice results in bimodal mortality with one-half of
homozygous mutant embryos dying at embryonic days 9 and 10,
and the remaining from massive hemorrhage within 2 hours of
birth.10 Surprisingly, no appreciable loss of homozygous mutant fish
embryos was observed until 28 dpf (Figure 2A). Given embryonic
hemorrhage observed in the murine model, we carefully examined
zebrafish at early stages of development. Larvae from heterozy-
gous incrosses were stained with o-dianisidine at 7 dpf and
examined for any evidence of hemorrhage. No differences in
o-dianisidine staining was seen between homozygous mutants
and their wild-type and heterozygous clutchmates (data not
shown). Given the extended survival and lack of hemorrhage in
early embryos and larvae, we hypothesized that there might be
residual expression or altered localization of f5 mRNA in mutants.
In zebrafish, the liver bud is first distinguishable at approximately
2 dpf, overlying the yolk sac to the left of midline.46 The liver grows
to its final dimensions between 2.5 and 3 dpf with outgrowth
complete by 5 dpf. Expression of f5 was examined in the
developing zebrafish at 5 dpf, and we confirmed localization to the
liver, but it was absent in f52/2 mutants (Figure 2E-F). These data
are consistent with nonsense mediated decay, which has been
demonstrated in other mutants.24,35 Reverse transcription PCR
indicated reduction of f5 in heterozygotes and significantly decreased
expression in homozygotes (Figure 2G). Given the early frame-
shift mutation, as well as lack of alternative products seen
with cDNA amplification, any translated protein is predicted to be
nonfunctional.
A
H2N B A3 C1 C2 COOH
303 317 2196203618777096661
143-160
Zebrafish
Mutation
Y1702CG97D R2074C    R2187CS83R
1546
A1 A2
B
f5+/+
f5-/- 49 base pair deletion
C
f5+/+
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f5+/- f5-/-
D
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300
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Figure 1. Targeting of the f5 locus using genome editing produces a null allele. (A) Structure of human F5; residue numbering is from the human protein. The
CRISPR/Cas9-induced mutation deletes what would be human residues 143 through 160 in the A1 domain and induces a frameshift. Numbered positions indicate location
of human mutations evaluated in Figure 5. (B) Sequence of 49-bp f5 exon 4 deletion. (C-D) Amplification of genomic and cDNA from f51/1, f51/2, and f52/2 fish demonstrates
the 49-bp deletion with no evidence for any other products.
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f5 homozygous mutants are unable to form thrombi
in an induced model of venous and arterial
endothelial injury
Because there was no spontaneous bleeding visible during the
embryonic/larval period, we evaluated whether f5 mutants respond
to induced trauma. We performed laser-mediated endothelial injury
on larvae generated from f51/2 incrosses, targeting the PCV
(orthologous to the mammalian inferior vena cava) at 3 dpf, the
dorsal aorta (orthologous to the mammalian aorta) at 9 dpf, and the
PMBC at 6 to 7 dpf. As expected, wild-type and f51/2 larvae
exhibited complete vessel occlusion within 2 minutes, whereas f52/2
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55
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21
(32%)
28
(43%)
16
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Figure 2. Phenotypes of f5 homozygous mutants reveal adult lethality and spontaneous hemorrhage in homozygous mutant adult fish. (A) Survival curves of
zebrafish offspring from f51/2 incrosses, starting at 2 months of age, demonstrate progressive loss of 90% of homozygotes by 7 mpf. Heterozygotes also demonstrate
statistically significant decreased survival compared with wild-type fish, with 50% mortality by 1.5 years of age. (B) Genotype distributions of offspring from f51/2 incrosses
evaluated at various stages demonstrate loss of homozygotes beginning at 28 dpf. (C) Spontaneous hemorrhage distal to the dorsal fin (arrow) in a 4-week-old homozygous
mutant fish. (D) Severe spontaneous periorbital hemorrhage (arrow) grossly visible in a 5-week-old homozygous mutant fish just before death. Similar bleeding was not
observed by blinded observers in heterozygous or wild-type clutchmates. Whole mount in situ hybridization with an antisense probe demonstrates localization of f5 expression
to the liver in f51/1 zebrafish at 5 dpf (E), but not in f52/2 mutants (F). (G) Total mRNA was prepared from pooled larvae (4 dpf, n 5 21 for each genotype) followed by
quantitative real-time PCR. Error bars represent standard deviation and statistical significance was determined by a Student t test.
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mutants failed to occlude (venous P # .0001, arterial P 5 .002,
PMBC P 5 .008 by the Mann-Whitney U test; Figure 3A-C).
Interestingly, the f51/2 larvae exhibited a trend toward longer time
to occlusion and increased numbers of larvae, which did not occlude
compared with wild-type, but this was not statistically significant. To
confirm the role of FV deficiency in this phenotype, as well as to rule out
off target mutations generated through genome editing, we injected
f51/2 incrosses with a zebrafish f5 cDNA under control of the zebrafish
ubiquitin (ubi) promoter (pDestTol2pA2_ubi:f5-p2A-EGFP).47 Subse-
quent injury of the PCV at 3 dpf demonstrated significant occlusion,
with rescue of the f52/2 phenotype in 73% of transgene-injected
embryos (Figure 3D, P , .0001 by the Mann-Whitney U test).
Inhibition of fibrinolysis has no significant effect on
the f52/2 larval hemostatic defect
Given the delayed lethality of homozygous mutants as compared
with the murine model, we suspected the possibility of alternate
pathways for fibrin production. To investigate this, we evalu-
ated whether treatment with an antifibrinolytic, e-aminocaproic
acid, could restore venous occlusion in homozygous mutants.
Previously, we demonstrated e-aminocaproic acid mediated
reversal of the hemostasis defect in fibrinogen-deficient at3
mutants,24 but not in f102/2 larvae.35 In f5 homozygous mutants,
laser-mediated endothelial injury revealed that treatment with
e-aminocaproic acid resulted in no statistically significant rescue
(Figure 4).
Evaluation of VUS in humans with F5 deficiency
through in vivo evaluation in zebrafish f52/2 mutants
With widespread availability and decreasing costs of sequencing,
increasing numbers of variants of unknow significance (VUS) are
being identified. We previously demonstrated proof of concept for
the use of zebrafish for this purpose and identified the causative
mutations in patients with FX deficiency.35 We evaluated 5 F5
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Figure 3. Effects of F5 deficiency on hemostasis in the venous and arterial circulation. (A) Laser-mediated endothelial injury of the PCV was performed on larvae at 3 dpf.
The time to occlusion was significantly prolonged in f52/2 larvae in comparison with f51/2 and f51/1 siblings (P , .0001, Mann-Whitney U test). (B-C) Endothelial injury was also
performed on the dorsal aorta at 9 dpf, and PMBC at 6 to 7 dpf with similar results. (D) Injection of wild-type zebrafish f5 cDNA under control of the zebrafish ubiquitin promoter into
1-cell stage embryos resulted in significant rescue of the PCV hemostatic defect at 3 dpf in 73% of f52/2 larvae when compared with uninjected mutants (P , .001). Note that variability
in the time to occlusion is a result of technical factors and heterozygosity in the genetic background. This has been seen with laser injury across other zebrafish mutants.
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mutations that had been identified in patients with clinical diagnoses
of FV deficiency (Table 2). All 5 of the affected amino acids are
conserved across species; thus, we engineered the variants into the
zebrafish f5 cDNA expression vector. These mutant plasmids were
injected into zebrafish embryos from f5 heterozygous incrosses at
the 1-cell stage, followed by laser-mediated endothelial injury at
3 dpf. Wild-type f5 expression plasmid, as well as the S83D,
R2187C, and R2074C substitutions, were able to reverse the
hemostatic defect. G97D demonstrated some activity, but was still
significantly reduced from wild-type, whereas Y1702C showed
almost no activity, correlating with the phenotypes observed in
patients.
Discussion
We report targeted mutagenesis of zebrafish f5 using
CRISPR/Cas9-mediated genome editing with development of a
model of type I FV deficiency. Given early lethality resulting
from hemorrhage in mice, we hypothesized that there would be
significant bleeding during embryonic/larval stages; however, a
large percentage of our homozygous mutants survived into adult-
hood. Embryos have a brief period of maternal RNA and protein
expression, which could be hypothesized to allow longer term
survival, but transcriptomic and proteomic data demonstrate that
there is no FV expression during this period.48,49 In contrast to f10
f5-/-
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Figure 4. Antifibrinolytic treatment with «-aminocaproic
acid does not restore hemostasis in f5 mutants.
Offspring from f51/2 incrosses were treated with
e-aminocaproic acid at 1 dpf and tested for venous
occlusion in response to laser-mediated endothelial
injury at 3 dpf, followed by genotyping. There was a
slight increase in the percentage of f52/2 embryos
that formed an occlusive thrombus (14.3% vs 5.5%)
compared with untreated clutchmates, but this was not
statistically significant. Horizontal bars represent the
median time to occlusion. ns, not significant.
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Figure 5. In vivo functional evaluation demonstrates
variable severity of defects in VUS. Human F5
variants were engineered into the orthologous positions in
the zebrafish f5 cDNA under the control the of the
ubiquitin promoter. Expression vectors were injected into
1-cell stage embryos from f5 heterozygous incrosses.
Laser-mediated endothelial injury was performed at
3 dpf and time to occlusion recorded, followed by
genotyping. Although Y1702C and G97D demonstrated
residual occlusion, they were unable to effectively rescue
(P , .0001, P 5 .002, respectively, by the Mann-Whitney
U test). Conversely, S83R, R2074C, and R2187C did
not show statistically significant differences from wild-type
rescue (not significant by the Mann-Whitney U test).
Horizontal bars represent the median time to occlusion.
Numbering reflects the human amino acid positions.
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mutants, which demonstrated a median survival of 1 to 2 mpf,35 f5
homozygotes demonstrated progressive loss with a median survival
of 4 mpf. This might be expected given the role of FV as a cofactor in
FX-mediated conversion of prothrombin to thrombin. Absence of a
cofactor might be better tolerated than absence of the protease
because the former condition could retain prothrombinase activity,
albeit at significantly lower efficiency. In contrast to f101/2 mutants,
fish heterozygous for the f5 mutation demonstrated decreased
survival compared with their wild-type counterparts, which we
hypothesize is due to a mild bleeding tendency that we found is
present as early as 3 dpf.
This is the third example of long-term survival of a coagulation factor
knockout in fish when compared with its murine counterpart.
Previously, we demonstrated that genome editing of zebrafish at324
and f1035 both result in survival into adulthood, despite mid-
gestation embryonic and/or neonatal lethality in mice. Examination
of the f52/2 mutant larval vasculature, including arterial and venous
vessels, demonstrated the inability to form thrombi in response to
endothelial injury. This suggests a nearly complete hemostatic
defect, so we speculate that the prolonged survival could be due to
1 or more of several mechanisms. Lethality in mice often occurs
in the neonatal period, with bleeding occurring secondary to
birth trauma. Yolk-based external, nonplacental development in
the laboratory aquatic environment likely poses fewer hemostatic
challenges than those encountered through the birthing process
and terrestrial environs. Systemic blood pressures in mice are
much higher than in zebrafish,50,51 and this may also play a role in
differential risk of bleeding. Although the coagulation cascade is
highly conserved between fish and mammals,30,52 it is possible that
fish have evolved unique factors or pathways that enable greater
tolerance of severe bleeding defects.
We have previously observed that the hemostatic defect in At3
coagulation factor–deficient larvae could be partially reversed by
treatment with the fibrinolysis inhibitor e-aminocaproic acid, but not
in f10 mutants.24,35 These data suggest that in the former case
there is enough residual fibrinogen and fibrin formation for there to
be an effect, and the latter is consistent with what appears to be a
complete block in fibrin production. We hypothesized that because
FX is a protease and FV is a cofactor, we might see evidence for a
low level of fibrin formation in the f5 mutants given that the protease
is still present. This was supported by the longer term survival
observed for the f5 homozygous mutants as compared with the
f10 knockout. However, the results of fibrinolysis inhibition on
induced thrombus formation were the same for both of these
common pathway mutations. These data suggest that, at least in the
short term of the endothelial injury assay, there is not enough fibrin
generated to form an occlusive thrombus.
The ability to evaluate specific human mutations for in vivo
phenotypic rescue is an invaluable tool for determining whether
novel mutations are deleterious. Because the promise of whole
genome and whole exome sequencing has become reality,
increasing numbers of VUS have been discovered, leaving
clinicians with difficulties when interpreting significance. Various
databases and common resources are available to aid in this
endeavor but do not provide a complete picture. In vivo evaluation of
such mutations provides an opportunity for further characterization
of the expected phenotype. Our ability to evaluate specific, clinically
identified mutations is dependent on conservation across species,
but this does not pose a significant hindrance because most
deleterious mutations occur within well conserved regions.53 This
evaluation is particularly useful within the field of coagulation where
preanalytic variables and coincident coagulation perturbations can
influence testing. Evaluation of VUS within the F5 locus can help to
identify causative mutations and provide a more nuanced estimation
of an individual’s patient’s bleeding phenotype. This is exceptionally
advantageous in FV deficiency, in which factor levels do not correlate
well with bleeding phenotype. Further evaluation of mutations in this
way may help to provide explanations for the differing phenotypes
seen between patients with similar factor levels.
We evaluated 5 mutations, 2 of which had previously been
described and investigated, and 3 VUS that were predicted to be
deleterious, all of which affect conserved residues from humans to
Table 2. Human F5 variants and clinical presentation
Human
mutation
Human amino
acid variant
Orthologous
zebrafish
amino acid
Protein context
human/fish
conservation FV antigen, % FV activity, % Allelic status Symptoms Reference
5279A.G p.Y1702C Y1571 CRAWAYYSAVN 1 ,1 Homozygous Bleeding tendency 54
CRTWTYYSAVN
**:*:******
79109C.T p.R2187C R2067 QSIALRLELFG NA 10 Compound heterozygosity with G97D No bleeding history Unpublished†
KSVTMRIELLG
:*:::*:**:*
32688G.A p.G97D G91 SKLSEGASYLD NA 10 Compound heterozygosity with R2187C No bleeding history Unpublished†
GKQSEGSKYFD
* ***: *:*
21193C.A p.S83R S77 ADKPLSIHPQG 23 4 Homozygous Unknown Unpublished†
ADHPCSLHPHG
**:* *:**:*
6394C.T p.R2074C R1940 EPFRARLNAQC 1-2.3 4 Homozygous Easy bruising 57
HPWYARLNKQG
*: **** **
Data are using F5-deficient patient plasma samples and activity refers to human F5 activity. Residue numbering begins subsequent to propeptide sequence (propeptide is 28 aa humans,
25 aa fish). Bold indicates the letter of the variant.
*, single fully conserved residue; :, conservation between groups of strongly similar properties; NA, not available.
†R.A. and S.D., unpublished data.
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zebrafish. Y1702C is a well-described missense mutation within the
A3 domain that causes protein instability and may interfere with
formation of disulfide bridges.54-56 Homozygosity results in severe
FV deficiency (FV antigen of 1% and activity of ,1%54) and no
significant rescue was observed in our evaluation. G97D (A1
domain) and R2187C (C2 domain) have not been previously
described but were found to be compound heterozygous in a
patient with an FV antigen level of 10%. G97D was not able to
restore venous occlusion in our analysis, although R2187C was able
to do so, implying that the latter is a less deleterious mutation that may
compensate clinically. S83R (A1 domain) has not previously been
described and was found to be homozygous in a patient with FV
antigen and activity levels of 23% and 4%, respectively. Despite its
low activity, it was able to effectively restore venous occlusion.
R2074C (also in the C2 domain) results in decreased secretion
of FV and enhanced intracellular degradation, and homozygosity
results in low but detectable FV activity (4%).57 Venous occlusion
was restored despite this defect, demonstrating that this molecule
does retain in vivo coagulant activity and strategies that mitigate the
secretion defect could be exploited as a clinical strategy to restore
hemostasis in affected patients. Because our assay is qualitative,
rather than quantitative, lack of rescue could be due to either type I or II
mutations (ie, reduced levels of FV antigen and/or activity).
All mutations demonstrated some ability to enhance occlusion, even
when statistically different from wild-type FV, demonstrating that
as in mammals, low levels of FV activity may be sufficient for
augmentation of thrombin generation in zebrafish as assessed by
our laser-induced endothelial injury model. This is consistent with
the relatively mild clinical bleeding phenotypes observed, even in
patients with unmeasurable FV activity. Half normal endogenous
thrombin potential has been shown with as little as 1% FV, with
absent or mild bleeding found in patients with endogenous
thrombin potentials of 30% of higher.14 Although minimal levels
are sufficient for thrombus formation in response to laser-induced
endothelial injury, there is a nonsignificant trend of prolonged time
to occlusion and/or total lack of occlusion in f51/2 zebrafish. We
hypothesize that this mild bleeding tendency over time is what
ultimately leads to the shortened survival seen in heterozygous fish
compared with wild-type siblings.
Interestingly, our rescue results somewhat correspond with both
bleeding symptomatology and reported factor activity levels.
Although the model was able to accurately predict bleeding
symptoms with the Y1702C mutation, it is likely that it would miss
subtle phenotypes such as the bruising tendency described in the
patient with the R2074C mutation. Historically, activity level has had
limited correlation with severity of bleeding.58 Our in vivo evaluation
could be beneficial in patients for whom factor activity levels do not
correlate with bleeding phenotype, performed early on, and provide
treatment and prognostic guidance. Ideally, we would have liked to
evaluate mutations from patients with identical laboratory testing
and divergent symptomatology. Unfortunately, given the limited
number of patient mutations available, none met these conditions;
this is a limitation to our assay. Because patients with identical
activity levels may have quite different bleeding phenotypes, this
tool may prove advantageous in providing a more nuanced view
of individual hemostasis. The fecundity of zebrafish and ease of
working with large numbers allow for easily repeated experiments,
which may ultimately unveil hemostatic differences which would
otherwise remain undiscovered.
There are several limitations to this approach. Primarily, despite the
conservation of the overall protein and affected amino acids, there
are still species-specific differences in other areas of the molecule.
We are also unable to directly measure levels of FV activity in
individual injected larvae and thus cannot quantitate the threshold
level required for rescue. Another limitation is that the model does
not currently take into account the FV platelet (thrombocytes in
zebrafish) pool, or tissue factor pathway inhibitor levels. Although
zebrafish thrombocytes do express FV,59 the ubi promoter drives
ubiquitous expression, so we are unable to differentiate between
effects within the plasma and platelet pools. However, for these
studies, thrombocytes are not relevant as they do not appear until
5 to 6 dpf of life, whereas our studies of hemostasis were largely
performed at 3 dpf. Future studies aim to address the role of these
other facets of hemostasis.
In summary, our model indicates strong conservation between
zebrafish and mammalian FV, including the site of its synthesis and
necessity for hemostasis. Surprisingly, embryos and larvae tolerate
what is a severe, lethal defect in mammals, allowing further studies
not available in the mouse. This viability, now across 3 coagula-
tion factor mutants with important roles in the common path-
way, suggests the possibility of species-specific factors enabling
survival. Further studies to identify such factors or other genetic
modifiers could lead to novel diagnostic and therapeutic modalities
for patients with hemostatic disorders.
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